NDA 021036 · Glaxosmithkline
Relenza
Zanamivir · Inhalation · Neuraminidase Inhibitor
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Oct 24, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1999
Jul 26, 1999
Approved uses
4
Original approval plus efficacy supplements
Registered trials
22
7 Phase 3, 3 recruiting
FAERS reports
2,525
1,595 serious, 250 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 23, 2026.
RELENZA, an influenza virus neuraminidase inhibitor (NAI), is indicated for: Treatment of acute, uncomplicated influenza type A and B infections in patients aged 7 years and older who have been symptomatic for no more than 2 days. ( 1.1 ) Prophylaxis of influenza in patients aged 5 years and older. ( 1.2 ) Important Limitations of Use: Not recommended for treatment or prophylaxis of influenza in: • Individuals with underlying airways disease. ( 5.1 ) Not proven effective for: • Treatment in individuals with underlying airways disease. ( 1.3 ) • Prophylaxis in nursing home residents. ( 1.3 ) Not a substitute for annual influenza vaccination. ( 1.3 ) Consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use RELENZA. ( 1.3 ) 1.1 Treatment of Influenza RELENZA (zanamivir) inhalation powder is indicated for treatment of uncomplicated acute illness due to influenza A and B virus in adults and pediatric patients aged 7 years and older who have been symptomatic for no more than 2 days. 1.2 Prophylaxis of Influenza RELENZA is indicated for prophylaxis of influenza in adults and pediatric patients aged 5 years and older. 1.3 Important Limitations of Use • RELENZA is not recommended for treatment or prophylaxis of influenza in individuals with underlying airways disease (such as asthma or chronic obstructive pulmonary disease) due to risk of serious bronchospasm [see Warnings and Precautions ( 5.1 )] . • RELENZA has not been proven effective for treatment of influenza in individuals with underlying airways disease. • RELENZA has not been proven effective for prophylaxis of influenza in the nursing home setting. • RELENZA is not a substitute for early influenza vaccination on an annual basis as recommended by the...
Mechanism: Zanamivir is an antiviral drug with activity against influenza virus [see Microbiology ( 12.4 )] .
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Mar 29, 2006 Supplement 8 · Efficacy · priority review LabelReviewLetter
- Mar 29, 2006 Supplement 9 · Efficacy · priority review
- Apr 26, 2000 Supplement 1 · Efficacy · priority review ReviewLetterLabel
- Jul 26, 1999 Original approval · Type 1 - New Molecular Entity · priority review LetterLabelReview
1 products under this application
- RELENZA · ZANAMIVIR 5MG · POWDER, INHALATION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Zanamivir" as an intervention, any sponsor and status, largest first.
- A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic InfluenzaPivotal-lookingRecruiting
University of OxfordAcademic, hospital or other
NCT05648448 · 3,000 participants (planned) · Start Feb 22, 2023 · Primary completion Jan 1, 2027
Drug: Oseltamivir; Favipiravir and 8 more · For: Influenza; Influenza, Human
Sites: Minas Gerais, Brazil; Vientiane, Laos; Kathmandu, Nepal · 4 sites in all
- A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With InfluenzaPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT01231620 · 626 participants · Start Jan 15, 2011 · Primary completion Mar 18, 2015
Drug: Zanamivir; Placebo to match zanamivir and 2 more · For: Influenza, Human
Sites: Birmingham, Alabama; Phoenix, Arizona; Chula Vista, California · 170 sites in all
- Evaluation of Efficacity and Safety of Oseltamivir and ZanamivirPivotal-lookingTerminated
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
NCT00799760 · 541 participants · Start Dec 2008 · Primary completion Nov 2009
Drug: oseltamivir + zanamivir; oseltamivir + zanamivir's placebo and 1 more · For: Gastric Influenza
Sites: Deûlémont, France
- Long Term Influenza Prophylaxis With Inhaled Zanamivir or Oral OseltamivirPivotal-lookingCompleted
University of OxfordAcademic, hospital or other
NCT00980109 · 390 participants · Start Sep 2009 · Primary completion Sep 2010
Drug: active oseltamivir; placebo capsule and 2 more · For: Influenza
Sites: Bangkok, Thailand · 2 sites in all
- Study to Assess Efficacy and Safety of Baloxavir Marboxil In Combination With Standard-of-Care Neuraminidase Inhibitor In Hospitalized Participants With Severe InfluenzaPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT03684044 · 363 participants · Start Jan 8, 2019 · Primary completion Mar 16, 2020
Drug: Baloxavir Marboxil · For: Influenza
Sites: Torrance, California; Denver, Colorado; Decatur, Georgia · 170 sites in all
- Efficacy and Safety of Inhaled Zanamivir in Treatment of Influenza A and B Virus Infections in ChinaPivotal-lookingCompleted
Jiangsu Simcere Pharmaceutical Co., Ltd.Industry
NCT01459081 · 298 participants · Start Oct 2011 · Primary completion Dec 2012
Drug: Zanamivir; Placebo · For: Influenza A Virus Infection; Influenza B Virus Infection
Sites: Changsha, China; Chengdu, China; Hangzhou, China · 12 sites in all
GlaxoSmithKlineGSK (GSK)
NCT01014988 · 202 participants · Start Nov 2009 · Primary completion Feb 2015
Drug: zanamivir aqueous solution · For: Influenza, Human
Sites: Birmingham, Alabama; Phoenix, Arizona; Little Rock, Arkansas · 110 sites in all
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT01052480 · 98 participants · Start Dec 2010 · Primary completion Mar 2015
Drug: Anti-Influenza Immune Plasma; Standard Care · For: Influenza A; Influenza B
Sites: Los Angeles, California; San Diego, California; Torrance, California · 35 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- abnormal behaviour399
- overdose395
- drug exposure during pregnancy244
- hallucination159
- drug exposure via breast milk123
- no adverse event117
- delirium115
- loss of consciousness104
- pyrexia100
- death70
- dyspnoea69
- aggression57
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 3 |
| 2005 | 8 |
| 2006 | 6 |
| 2007 | 113 |
| 2008 | 143 |
| 2009 | 933 |
| 2010 | 312 |
| 2011 | 317 |
| 2012 | 91 |
| 2013 | 60 |
| 2014 | 114 |
| 2015 | 78 |
| 2016 | 77 |
| 2017 | 32 |
| 2018 | 49 |
| 2019 | 94 |
| 2020 | 44 |
| 2021 | 24 |
| 2022 | 8 |
| 2023 | 7 |
| 2024 | 5 |
| 2025 | 5 |
| 2026 | 2 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Relenza (Zanamivir)
2024 spending
$13K
Beneficiaries
114
194 claims
Per beneficiary
$113
$2.89 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $31,974 |
| 2021 | $11,647 |
| 2022 | $16,311 |
| 2023 | $13,400 |
| 2024 | $12,885 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Antivirals for treatment of severe influenza: a systematic review and network meta-analysis of randomised controlled trials.
Gao Y, Guyatt G, Uyeki TM, et al. · Lancet 2024 · Systematic Review, Research Support, Non-U.S. Gov't
- Antivirals for post-exposure prophylaxis of influenza: a systematic review and network meta-analysis.
Zhao Y, Gao Y, Guyatt G, et al. · Lancet 2024 · Systematic Review, Research Support, Non-U.S. Gov't
- Influenza.
Jefferson T · BMJ Clin Evid 2009 · Systematic Review
- Comparison of Antiviral Agents for Seasonal Influenza Outcomes in Healthy Adults and Children: A Systematic Review and Network Meta-analysis.
Liu JW, Lin SH, Wang LC, et al. · JAMA Netw Open 2021 · Systematic Review, Network Meta-Analysis
- Combining baloxavir marboxil with standard-of-care neuraminidase inhibitor in patients hospitalised with severe influenza (FLAGSTONE): a randomised, parallel-group, double-blind, placebo-controlled, superiority trial.
Kumar D, Ison MG, Mira JP, et al. · Lancet Infect Dis 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Neuraminidase inhibitors for preventing and treating influenza in adults and children.
Jefferson T, Jones MA, Doshi P, et al. · Cochrane Database Syst Rev 2014 · Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: GSK
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.